表紙
市場調査レポート

ラニビズマブの中国市場の分析

Investigation Report on China Ranibizumab Market, 2012-2019

発行 China Research and Intelligence 商品コード 336268
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
ラニビズマブの中国市場の分析 Investigation Report on China Ranibizumab Market, 2012-2019
出版日: 2015年07月24日 ページ情報: 英文 20 Pages
概要

ラニビズマブは加齢性の黄斑変種 (AMD) の治療薬で、中国では2012年にCFDA (国家食品薬品監督管理総局) により認証されました。現時点で上市されたのはLucentis (Novartisが開発) だけですが、2013年12月には国内系メーカーが自主開発した治療薬も認証が下りています。ラニビズマブ市場は上市移行急速に拡大しており、国内19ヶ所の病院での売上高は2億4500万人民元 (2014年)、過去3年間の市場成長率は200%に達しています。

当レポートでは、中国におけるラニビズマブの市場について分析し、全体的な市場規模の動向(過去3年間分)や国内価格の動向、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査・推計しております。

第1章 ラニビズマブの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のラニビズマブ市場の概況

  • 中国国内でのラニビズマブの特許出願・認証状況
  • 主要メーカー
  • 市場規模

第3章 ラニビズマブの販売状況の分析 (過去3年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 中国のラニビズマブ市場:主要メーカーの市場シェアの分析 (過去3年間分)

  • 市場シェア (販売額ベース)
  • 市場シェア (販売量ベース)

第5章 中国のラニビズマブ市場:剤形別の分析 (過去3年間分)

  • 剤形別の市場シェア (販売額ベース)
  • 剤形別の市場シェア (販売量ベース)

第6章 ラニビズマブの病院向け基準価格

第7章 中国国内のラニビズマブの主要メーカー (過去3年間分)

第8章 中国のラニビズマブ市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の見通し

図表一覧

目次
Product Code: 1507276

As macular is the area responsible for high-resolution vision near the center of the retina, macular degeneration, once occurred, will lead to a loss of central vision and distorted vision in the form of metamorphopsia or even irreversible blindness. According to a report published by WHO in 2012, 30 million people suffer from macular degeneration globally, among which about 500,000 end up in blindness per year. In the US, blindness cases caused by macular degeneration outnumbers those caused by glaucoma, cataract and diabetic retinopathy. According to a Chinese investigation in 2012, the incidence of macular degeneration reaches up to 15.5% among old people aged above 50 and 20.2% among those aged above 70. With ageing population, the incidence of macular degeneration will continue to go up.

Developed by Novartis, ranibizumab was approved by CFDA to treat wet age-related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self-developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA's approval.

Ranibizumab develops fast after entering China, sales value in 19 sample hospitals in key cities in 2014 reaching CNY 245 million with a year-on-year growth of 26.29% and CAGR during the last three years reaching 200%. With ageing population, the incidence of macular degeneration goes up gradually. Hence the vast demand for ranibizumab in China. Currently, ranibizumab injections in mainland China all come from Novatis. But as conbercept ophthalmic injection is proved by the clinical studies to improve vision better with a lower administration frequency, it is expected to break the monopoly of Novatis in the wet AMD drug market in the next few years.

Readers can get at least the following information from this report:

  • market size of ranibizumab in China
  • competitive landscape of ranibizumab in Chinese market
  • price of ranibizumab made by different enterprises in China
  • market outlook of ranibizumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • manufacturers of ophthalmic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Ranibizumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Ranibizumab in China

  • 2.1. Patent Status and Approval Information of Ranibizumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Ranibizumab in China, 2012-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Ranibizumab in China, 2012-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Ranibizumab in China, 2012-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Ranibizumab in Chinese Hospitals in 2014

7. Major Manufacturers of Ranibizumab in Chinese Market, 2012-2014

8. Market Outlook of Ranibizumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Ranibizumab in China
  • Chart Registration Information of Ranibizumab in China
  • Chart Sales Status of Ranibizumab in China
  • Chart Sales Value of Ranibizumab in China, 2012-2014
  • Chart Sales Value of Ranibizumab in Some Regions in China, 2012-2014
  • Chart Sales Volume of Ranibizumab in China, 2012-2014
  • Chart Sales Volume of Ranibizumab in Some Regions in China, 2012-2014
  • Chart Price of Ranibizumab Made by Novartis in Some Chinese Cities in 2014
Back to Top